Here's My Top Stock to Buy for November

Boeing reported a $745 billion backlog, including $612 billion for Commercial Airplanes, while its nine-month segment results showed Global Services operating at an 18.2% margin and Defense, Space & Security back in profit at a 3.1% margin; Commercial Airplanes lost $1.582 billion. Management now expects 737 MAX production to stabilize at 47 per month by 2027 and targets 52 per month in the second half of that year; the article argues this may leave upside to free-cash-flow guidance of $2 billion in 2026, $3 billion in 2027, $6 billion in 2028 and $10 billion in 2029. Certification of the 777X is targeted for 2027, with first delivery to follow, and the author views Boeing as attractive despite execution risks.

Analysis

The key asymmetry is that Boeing’s backlog has value only if it converts into on-time deliveries and cash; it is not a substitute for execution. Production-rate targets are especially easy to overread: actual FCF also depends on certification, delivery timing, supplier throughput, quality costs, and cash tied up in work-in-process. A production ramp without delivery and cash-conversion evidence would weaken the bullish case.

Near term, the article offers limited grounds for a catalyst trade: the 737 MAX schedule has already moved out, while the largest cash-flow upside is back-end loaded. Over 1–3 months, watch for evidence that output and deliveries are converging, supplier constraints are easing, and management’s FCF bridge is holding. Over 6–18 months, sustained commercial production and fewer fixed-price defense losses could make the recovery more durable. Conversely, a renewed certification or quality setback could raise costs and delay cash realization; the 777X remains a separate timing risk.

The contrarian point is that an apparently conservative FCF path can still be too optimistic if it assumes production translates smoothly into deliveries and cash. BGS and improving BDS may cushion the consolidated business, but neither removes BCA’s execution risk. The article’s positive view on DOD contract terms is not enough to infer a broad improvement in defense margins; verify the actual provisions and their applicability before extrapolating to Boeing. The supplied forward P/FCF figures also rely on distant estimates, so they should not be treated as current-cycle valuation support.

Key Decisions for Investors

• Consider a staged, small long in BA rather than buying the full recovery thesis at once. Add only after reported deliveries and FCF conversion support the production ramp; the upside case is improving cash generation, while the principal risk is further schedule slippage and cash absorption.
• Treat 737 MAX output, deliveries, and free cash flow as separate checkpoints. If production rises but deliveries or cash conversion do not follow, pause adds and reassess the thesis rather than crediting production targets as realized earnings.
• Monitor certification and delivery milestones for the 777X, supplier throughput, and quality-related costs over the next 6–18 months. A material delay or deterioration in guidance would falsify the improving-execution thesis.
• Do not use LMT as an automatic hedge or assume Boeing benefits from terms in another defense contractor’s agreements. Review the specific DOD provisions and Boeing program exposure before making a defense-contract repricing trade.